AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma

Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17:351–9.

Google Scholar 

Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13:472–82.

Google Scholar 

Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297–308.

Google Scholar 

Zanotelli MR, Goldblatt ZE, Miller JP, Bordeleau F, Li J, VanderBurgh JA, et al. Regulation of ATP utilization during metastatic cell migration by collagen architecture. MBoC. 2018;29:1–9.

Google Scholar 

Leiter U, Keim U, Garbe C. Epidemiology of Skin Cancer: Update 2019. Adv Exp Med Biol. 2020;1268:123–39.

Google Scholar 

Baenke F, Chaneton B, Smith M, Van Den Broek N, Hogan K, Tang H, et al. Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol Oncol. 2016;10:73–84.

Google Scholar 

Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, et al. Changes in aged fibroblast lipid metabolism induce age-dependent melanoma cell resistance to targeted therapy via the fatty acid transporter FATP2. Cancer Discov. 2020;10:1282–95.

Google Scholar 

Vivas-García Y, Falletta P, Liebing J, Louphrasitthiphol P, Feng Y, Chauhan J, et al. Lineage-restricted regulation of SCD and fatty acid saturation by MITF controls melanoma phenotypic plasticity. Mol Cell. 2020;77:120–137.e9.

Google Scholar 

Liu Y, Zhang X, Wang G, Cui X. Triple combination therapy with PD-1/PD-L1, BRAF, and MEK inhibitor for stage III-IV melanoma: a systematic review and meta-analysis. Front Oncol. 2021;11:693655.

Google Scholar 

Larkin J. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76.

Google Scholar 

Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018;30:125–33.

Google Scholar 

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. 2014. https://doi.org/10.1056/NEJMoa1412690.

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma. Nature. 2010;467:596–9.

Google Scholar 

Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.

Google Scholar 

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:603–15.

Google Scholar 

Shirley M. Encorafenib and binimetinib: first global approvals. Drugs. 2018;78:1277–84.

Google Scholar 

Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008;68:650–6.

Google Scholar 

Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, et al. Toward minimal residual disease-directed therapy in melanoma. Cell. 2018;174:843–855.e19.

Google Scholar 

Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33:890–904.e5.

Google Scholar 

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712.

Google Scholar 

Goding CR, Arnheiter H. MITF-the first 25 years. Genes Dev. 2019;33:983–1007.

Google Scholar 

Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006;20:3426–39.

Google Scholar 

Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene. 2012;31:2461–70.

Google Scholar 

Falletta P, Sanchez-Del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, et al. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev. 2017;31:18–33.

Google Scholar 

Falletta P, Goding CR, Vivas-García Y. Connecting metabolic rewiring with phenotype switching in melanoma. Front Cell Dev Biol. 2022;10:930250.

Google Scholar 

Ferguson J, Smith M, Zudaire I, Wellbrock C, Arozarena I. Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth. Oncotarget. 2017;8:32946–59.

Google Scholar 

Louphrasitthiphol P, Ledaki I, Chauhan J, Falletta P, Siddaway R, Buffa FM, et al. MITF controls the TCA cycle to modulate the melanoma hypoxia response. Pigment Cell Melanoma Res. 2019;32:792–808.

Google Scholar 

Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell. 2013;23:302–15.

Google Scholar 

Corre S, Tardif N, Mouchet N, Leclair HM, Boussemart L, Gautron A, et al. Sustained activation of the aryl hydrocarbon receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nat Commun. 2018;9:4775.

Google Scholar 

Paris A, Tardif N, Baietti FM, Berra C, Leclair HM, Leucci E, et al. The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma. EMBO Mol Med. 2022;14:e15677.

Google Scholar 

Granados K, Poelchen J, Novak D, Utikal J. Cellular reprogramming-a model for melanoma cellular plasticity. Int J Mol Sci. 2020;21:E8274.

Google Scholar 

Dietrich C. Antioxidant functions of the aryl hydrocarbon receptor. Stem Cells Int. 2016;2016:e7943495.

Google Scholar 

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.

Google Scholar 

Westermann B. Bioenergetic role of mitochondrial fusion and fission. Biochim Biophys Acta. 2012;1817:1833–8.

Google Scholar 

Ghaffarian-Bahraman A, Arabnezhad M-R, Keshavarzi M, Davani-Davari D, Jamshidzadeh A, Mohammadi-Bardbori A. Influence of cellular redox environment on aryl hydrocarbon receptor ligands induced melanogenesis. Toxicol Vitro. 2022;79:105282.

Google Scholar 

Turner JA, Paton EL, Van Gulick R, Stefanoni D, Cendali F, Reisz J, et al. BRAF modulates lipid use and accumulation. Cancers. 2022;14:2110.

Google Scholar 

Zhou N, Bao J. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database. 2020;2020:baaa021.

Google Scholar 

Vendramin R, Katopodi V, Cinque S, Konnova A, Knezevic Z, Adnane S, et al. Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma. J Exp Med. 2021;218:e20210571.

Google Scholar 

Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem Biol. 2019;26:623–633.e9.

Google Scholar 

Talty R, Bosenberg M. The role of ferroptosis in melanoma. Pigment Cell Melanoma Res. 2021. https://doi.org/10.1111/pcmr.13009.

Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin-Sandoval MS, et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature. 2020;585:113–8.

Google Scholar 

Wang H, Zhang H, Chen Y, Wang H, Tian Y, Yi X, et al. Targeting Wnt/β-catenin signaling exacerbates ferroptosis and increases the efficacy of melanoma immunotherapy via the regulation of MITF. Cells. 2022;11:3580.

Google Scholar 

Liu X, Li Z, Li M, Chai J, He S, Wu J, et al. Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF. Oncol Rep. 2020;44:360–70.

Google Scholar 

Shao H, Teramae D, Wells A. Axl contributes to efficient migration and invasion of melanoma cells. PLoS ONE. 2023;18:e0283749.

Google Scholar 

Cui J-X, Xu X-H, He T, Liu J-J, Xie T-Y, Tian W, et al. L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis. J Exp Clin Cancer Res. 2023;42:52.

Google Scholar 

Eleftheriadis T, Pissas G, Filippidis G, Liakopoulos V, Stefanidis I. Reoxygenation induces reactive oxygen species production and ferroptosis in renal tubular epithelial cells by activating aryl hydrocarbon receptor. Mol Med Rep. 2021;23:41.

Google Scholar 

Kwon O-S, Kwon E-J, Kong H-J, Choi J-Y, Kim Y-J, Lee E-W et al. Systematic identification of a nuclear receptor-enriched predictive signature for erastin-induced ferroptosis. Redox Biol. 2020;37:101719.

Gagliardi M, Saverio V, Monzani R, Ferrari E, Piacentini M, Corazzari M. Ferroptosis: a new unexpected chance to treat metastatic melanoma? Cell Cycle. 2020;19:2411–25.

Google Scholar 

Wang H-C, Liu K-Y, Wang L-T, Hsu S-H, Wang S-C, Huang S-K. Aryl hydrocarbon receptor promotes lipid droplet biogenesis and metabolic shift in respiratory Club cells. Hum Cell. 2021;34:785–99.

Google Scholar 

Tang F, Li S, Liu D, Chen J, Han C. Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis. Transl Cancer Res. 2020;9:1584–93.

Google Scholar 

Wang M, Li S, Wang Y, Cheng H, Su J, Li Q. Gambogenic acid induces ferroptosis in melanoma cells undergoing epithelial-to-mesenchymal transition. Toxicol Appl Pharmacol. 2020;401:115110.

Google Scholar 

Talebi A, de Laat V, Spotbeen X, Dehairs J, Rambow F, Rogiers A, et al. Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy. J Exp Clin Cancer Res. 2023;42:92.

Google Scholar 

Vergani E, Beretta GL, Aloisi M, Costantino M, Corno C, Frigerio S, et al. Targeting of the lipid metabolism impairs resistance to BRAF kinase inhibitor in melanoma. 2022;10:927118.

Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 2006;1:3159–65.

Google Scholar